NEW YORK, Dec 30 (Reuters) - Drugmakers including Pfizer Inc (PFE.N), GlaxoSmithKline PLC (GSK.L), Bristol Myers Squibb (BMY.N), AstraZeneca PLC (AZN.L) and Sanofi SA (SASY.PA) plan to raise prices in the United States on more than 350 unique drugs in early January, according to data analyzed by healthcare research firm 3 Axis Advisors."Drug makers have to take a harder look at calibrating those launch prices out of the gate ... so they don't box themselves into the point where in the future, they can't price increase their way back into profitability," he said.That was followed by GSK, with planned increases so far on 26 unique drugs, including nearly a 7% increase on its popular shingles vaccine Shingrix.A Pfizer spokesperson said in an email that the company's average list prices for drugs and vaccines in 2023 are well below overall inflation at approximately 3.6%, noting that the increases are needed to support investments in drug discovery."AstraZeneca has always taken a thoughtful approach to pricing, and we continue to do so, considering many factors," said company spokesman Brendan McEvoy."